secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2026-07-31T20:44:28+00:00
Accession:  0001339970-26-000042
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma regains global rights to efzofitimod after Kyorin termination
-------------------------------------------------------------------------

- Kyorin terminated collaboration; aTyr and Kyorin entered termination agreement effective July 30, 2026.
- Exclusive rights to develop and commercialize efzofitimod in Japan revert to aTyr.
- aTyr now holds global rights to efzofitimod for all forms of interstitial lung disease.
- Termination includes wind-down of ancillary agreements and transfer of data and orphan drug designation.
- No outstanding payments from Kyorin to aTyr regarding development costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000042/0001339970-26-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000042/atyr-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001339970-26-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer